Expert warns of thiazolidinedione-related bone loss in diabetes

08/18/2011 | InternalMedicineNews.com (free registration)

Following the results of several studies, rheumatologist Jonathan Graf has cautioned patients with diabetes to avoid using thiazolidinediones as they appear to reduce bone density and elevate fracture risk. However, taking lower doses of thiazolidinediones in combination with either metformin or incretin drugs may still help patients achieve efficient diabetes control without risking bone health, Graf said.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC